Compare HRMY & HSAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRMY | HSAI |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | 2020 | 2021 |
| Metric | HRMY | HSAI |
|---|---|---|
| Price | $41.14 | $16.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $44.11 | $31.58 |
| AVG Volume (30 Days) | 849.5K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 1.84 | N/A |
| Revenue | ★ $868,453,000.00 | N/A |
| Revenue This Year | $19.75 | $46.29 |
| Revenue Next Year | $12.88 | $41.32 |
| P/E Ratio | ★ $22.37 | $61.18 |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $14.29 |
| 52 Week High | $43.49 | $29.35 |
| Indicator | HRMY | HSAI |
|---|---|---|
| Relative Strength Index (RSI) | 52.86 | 42.61 |
| Support Level | $40.92 | $15.81 |
| Resistance Level | $43.38 | $19.29 |
| Average True Range (ATR) | 1.21 | 0.51 |
| MACD | -0.27 | -0.12 |
| Stochastic Oscillator | 40.51 | 8.69 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Hesai Group is engaged in the development, manufacture, and sales of three-dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with enhanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. Geographically, the company operates in North America, Mainland China, Europe, and Other regions.